Bayzed Health Group H1 Loss Widening Challenges Long Running Narrative Of Improving Profitability

Simply Wall St.04-02

Bayzed Health Group (SEHK:2609) has reported its FY 2025 first half with revenue of C$574.7 million and a basic EPS loss of C$0.020948, setting the tone for another period where the top line and per ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624550490?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6033000-choice2-main-header/1585186569462","is_english":true,"pubTime":"2026-04-02 20:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624550490","market":"hk","top_or_hot":-1,"title":"Bayzed Health Group H1 Loss Widening Challenges Long Running Narrative Of Improving Profitability","media":"Simply Wall St.","content":"<div>\n<p>Bayzed Health Group (SEHK:2609) has reported its FY 2025 first half with revenue of C$574.7 million and a basic EPS loss of C$0.020948, setting the tone for another period where the top line and per ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/healthcare/hkg-2609/bayzed-health-group-shares/news/bayzed-health-group-h1-loss-widening-challenges-long-running\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bayzed Health Group H1 Loss Widening Challenges Long Running Narrative Of Improving Profitability</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBayzed Health Group H1 Loss Widening Challenges Long Running Narrative Of Improving Profitability\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-02 20:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/healthcare/hkg-2609/bayzed-health-group-shares/news/bayzed-health-group-h1-loss-widening-challenges-long-running><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bayzed Health Group (SEHK:2609) has reported its FY 2025 first half with revenue of C$574.7 million and a basic EPS loss of C$0.020948, setting the tone for another period where the top line and per ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/healthcare/hkg-2609/bayzed-health-group-shares/news/bayzed-health-group-h1-loss-widening-challenges-long-running\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02609","symbol_name":"佰泽医疗","start_time":0,"source_url":"https://simplywall.st/stocks/hk/healthcare/hkg-2609/bayzed-health-group-shares/news/bayzed-health-group-h1-loss-widening-challenges-long-running","article_id":"2624550490","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6033000-choice2-main-header/1585186569462"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/healthcare/hkg-2609/bayzed-health-group-shares/news/bayzed-health-group-h1-loss-widening-challenges-long-running","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2624550490","pubTimestamp":1775133255,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Bayzed Health Group (SEHK:2609) has reported its FY 2025 first half with revenue of C$574.7 million and a basic EPS loss of C$0.020948, setting the tone for another period where the top line and per share performance remain firmly in focus. Over the recent periods, the company has seen revenue move between C$570.9 million and C$617.9 million per half while basic EPS has ranged from a loss of C$0.00161 to C$0.022396, underscoring a pattern of meaningful sales with persistent, if fluctuating,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"02609":"佰泽医疗","BK1209":"保健护理机构"},"translate_title":"Bayzed Health Group上半年亏损扩大对提高盈利能力的长期叙述构成挑战","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02609":0.9},"content_text":"Bayzed Health Group (SEHK:2609) has reported its FY 2025 first half with revenue of C$574.7 million and a basic EPS loss of C$0.020948, setting the tone for another period where the top line and per share performance remain firmly in focus. Over the recent periods, the company has seen revenue move between C$570.9 million and C$617.9 million per half while basic EPS has ranged from a loss of C$0.00161 to C$0.022396, underscoring a pattern of meaningful sales with persistent, if fluctuating, losses. For investors, the latest numbers keep attention squarely on how efficiently that revenue is being converted into profit and what that means for margins over time. See our full analysis for Bayzed Health Group. With the headline figures on the table, the next step is to set these results against the widely followed Bayzed Health Group narratives to see which stories the numbers support and which they begin to challenge. Curious how numbers become stories that shape markets? Explore Community Narratives SEHK:2609 Earnings & Revenue History as at Apr 2026 AdvertisementLosses Narrow Over Five Years, But H1 FY 2025 Steps Back  For H1 FY 2025, Bayzed Health Group reported net income excluding extra items of a C$27.6 million loss on C$574.7 million of revenue, compared with a C$1.9 million loss on C$617.9 million of revenue in H2 FY 2024 and a C$11.5 million loss on C$570.9 million of revenue in H1 FY 2024. Bears who focus on the current loss profile can point to the wider H1 FY 2025 loss and basic EPS of a C$0.020948 loss. This sits alongside a multi year trend of losses reducing by about 35% a year, which creates tension between the short term setback and the longer term improvement in the earnings track record.\n     The trailing 12 month net loss excluding extra items is C$13.0 million on C$1.12b of revenue, compared with C$29.5 million of losses on C$1.19b of revenue one period earlier. This supports the idea that the overall loss run rate has been coming down over time. Basic EPS on a trailing 12 month basis also sits at a C$0.01 loss compared with a C$0.022396 loss a period earlier, so while the latest half year is weak, the broader picture still lines up with the long run reduction in losses that skeptics sometimes underplay.    P/S Of 4.5x Versus 1x Industry Keeps Expectations High  The shares trade on a trailing P/S of 4.5x, against a Hong Kong healthcare industry average of 1x and a peer average of 1.6x, which means investors are currently paying a higher price per dollar of sales than the sector and close comparable companies. Bears argue that paying 4.5x sales for an unprofitable company sets a high bar, and the valuation records give them some support while also highlighting areas where the cautious view is tested.\n     The stock price of HK$4.34 paired with C$1.12b of trailing 12 month revenue implies the market is already assigning a premium to Bayzed Health Group relative to the 1x industry P/S. Any slowdown in revenue or delay in reaching profitability can weigh more heavily when the starting multiple is above peers. At the same time, the absence of flagged company specific risks in the supplied material means the bear case is currently built more on valuation and profitability metrics than on disclosed operational or balance sheet issues. This is a different profile from companies where there are already clear problem areas identified.    DCF Fair Value Of HK$7.11 Versus HK$4.34 Spot Price  A DCF fair value of HK$7.11 compared with a current share price of HK$4.34 suggests the stock is trading about 39% below that model based estimate. Supporters of a more bullish stance see the combination of shrinking losses over five years and a price below the DCF fair value as important, even though the company is still unprofitable on the trailing 12 month view.\n     The reduction in losses at about 35% per year over the past five years means that C$13.0 million of trailing 12 month losses is being viewed in the context of a longer series of gradually smaller deficits. This can help explain why the DCF model arrives at HK$7.11 even while EPS is still negative. With C$1.12b of trailing revenue alongside that HK$4.34 share price, the idea that investors are paying a premium P/S multiple but a discount to the DCF estimate sums up the tension that bullish holders point to when arguing that the current valuation may not fully reflect the earnings trajectory implied in the model.    If you want to see how other investors are connecting these earnings trends with long term storylines and valuation views, it is worth reading the shared community perspectives in more detail Curious how numbers become stories that shape markets? Explore Community Narratives. Next Steps Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Bayzed Health Group's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move. If the mixed messages around losses, revenue and valuation leave you unsure, that is exactly when it helps to look closer at the underlying data yourself. Compare the numbers across periods and use tools that highlight the potential upside many investors are already focused on with 2 key rewards See What Else Is Out There Bayzed Health Group combines consistent revenue with ongoing losses and a higher than average P/S multiple, so profitability and valuation resilience remain key pressure points. If that mix of steady sales, continued losses and a rich revenue multiple feels uncomfortable, compare it with companies that focus more on income returns through 451 dividend fortresses.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Bayzed Health Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624550490","isCrawlerRequest":true}